Compare BAFN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BAFN | ANL |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | 123 |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 293.4M |
| IPO Year | 2021 | 2022 |
| Metric | BAFN | ANL |
|---|---|---|
| Price | $5.61 | $7.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 10.0K | ★ 215.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 133.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.23 | $0.88 |
| 52 Week High | $19.00 | $12.09 |
| Indicator | BAFN | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 47.12 |
| Support Level | N/A | $7.21 |
| Resistance Level | $8.26 | $9.98 |
| Average True Range (ATR) | 0.43 | 1.05 |
| MACD | -0.09 | -0.31 |
| Stochastic Oscillator | 25.26 | 25.68 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.